Key result
Comorbidities in newly diagnosed type 2 diabetes are linked to ~220% higher microalbuminuria prevalence.
Why the study?
Microalbuminuria is an early marker of diabetic nephropathy that may lead to chronic renal failure if not recognized and treated early in newly detected type 2 diabetes patients.
Is the prevalence of microalbuminuria higher in newly diagnosed type 2 diabetes patients with hypertension, dyslipidaemia, and obesity compared to those without these comorbidities?
Observational (n=90)
No
Is the prevalence of microalbuminuria higher in newly diagnosed type 2 diabetes patients with hypertension, dyslipidaemia, and obesity compared to those without these comorbidities?
Microalbuminuria is highly prevalent in newly diagnosed type 2 diabetes, especially in those with concurrent hypertension, dyslipidaemia, and obesity, highlighting the need for early screening.
May support microalbuminuria screening in new T2DM; leaves open independent links with hypertension, dyslipidaemia, or obesity.
Background: Microalbuminuria is one of the earliest markers of diabetic nephropathy, and if not recognized and treated early it may lead to diabetic nephropathy resulting in chronic renal failure. Aims and Objective: The aim of the current study was to find out the prevalence of microalbuminuria among newly detected Type 2 diabetic patients and also compare prevalence of microalbuminuria in patients with or without hypertension, dyslipidaemia and obesity. Materials and Methods: In this retrospective study, we analysed 90 patients with new onset type 2 diabetes mellitus. We divided the patients into two groups, group 1 with comorbidities like hypertension, dyslipidaemia and obesity (50 patients) and group 2 without comorbidities (40 patients). We analysed urinary microalbumin level in all patients and compared the prevalence of microalbuminuria between group 1 and group 2. Results: In our cohort of 90 patients, urinary microalbuminuria was found in 30 patients (33.3%). When we divided these nephropathy patients to group1 and group 2, we observed that group 1 with comorbidities had higher percentage of nephropathy patients i.e 24 out of 50(48%). Group 2 with 40 patients had only 6 patients with microalbiminuria ie 6 out of 40(15%). Incidence of microalbiminuria was higher in patients with hypertension, dyslipidaemia and obesity. Conclusions: We conclude that incidence of microalbiminuria is much more common in newly diagnosed type 2 diabetes. We also conclude that hypertension, obesity and hypercholesterolemia are risk factors for nephropathy and urinary microalbuminuria appears to be much more sensitive than serum creatinine as screening tool to detect diabetic nephropathy.
No takes yet. Share an insight, caveat, or question.
Shrikrishna V. Acharya (2020) conducted an observational in Newly detected Type 2 diabetes mellitus (n=90). Comorbidities (hypertension, dyslipidaemia, and/or obesity) vs. No comorbidities was evaluated on Prevalence of microalbuminuria. The prevalence of microalbuminuria in newly diagnosed type 2 diabetes was 33.3% overall, and was notably higher in patients with comorbidities such as hypertension, dyslipidaemia, or obesity (48%) compared to those without (15%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: